Investigating the effects of aging on insulin resistance and obesity
In French AGIR Means to Get Into Action. This is the Generic Title of Our Study.
This study is testing how physical activity can help older adults aged 60-80 improve their insulin sensitivity and manage obesity as they age.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 60 Years to 80 Years |
| Sex | All |
| Sponsor | University of Lausanne Academic / other |
| Locations | 2 sites (Bern and 1 other locations) |
| Trial ID | NCT01224886 on ClinicalTrials.gov |
What this trial studies
This study examines the relationship between aging, insulin resistance, and obesity in older adults. It focuses on how physical inactivity and ectopic lipid accumulation may contribute to insulin resistance, a key factor in the development of type 2 diabetes. Participants aged 60-80, whether sedentary or highly trained, will engage in a physical activity intervention to assess its impact on their insulin sensitivity. The study aims to clarify the role of aging in insulin resistance amidst the rising prevalence of obesity and diabetes in older populations.
Who should consider this trial
Good fit: Ideal candidates are adults aged 60-80 who are either sedentary or highly trained and have a BMI between 18-40.
Not a fit: Patients with known diabetes, significant cardiovascular or other health issues, or those on medications affecting glucose metabolism may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for managing insulin resistance and reducing the risk of type 2 diabetes in older adults.
How similar studies have performed: Other studies have shown promising results in addressing insulin resistance through physical activity, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 60-80 * Sedentary or highly trained * BMI 18-40 * Non-Smoker * Normal glucose tolerance or impaired glucose tolerance * Willingness to comply with the protocol Exclusion Criteria: * Contraindication to moderate exercise or clinical conditions precluding from joining an exercise program, such as clinically significant cardiovascular disease, peripheral vascular disease, uncontrolled hypertension, neurological or orthopedic disease * Recent weight loss or weight gain * Known diabetes * Known drugs to affect glucose homeostasis such as nicotinic acid, glucocorticoids * Severe anemia or lipid disturbances, hepatic or renal disease * Recent history of cancer * Hypothyroidism * Recent hormone replacement therapy * Known allergy to lidocaine or other local anesthetic * Positive stress test * Active alcohol or substance abuse
Where this trial is running
Bern and 1 other locations
- University of Bern — Bern, Switzerland (Active_not_recruiting)
- UNIL and CHUV — Lausanne, Switzerland (Recruiting)
Study contacts
- Principal investigator: Francesca Amati, MD,PhD — University of Lausanne
- Study coordinator: Francesca Amati, MD, PhD
- Email: francesca.amati@unil.ch
- Phone: +41 21 692 5552
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.